INO
Inovio Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.43
+5.15%Aug 25, 2026, 01:56 UTC
Inovio Pharmaceuticals reported first-half 2026 revenue of 1.137 billion yuan, up 55.5% year-over-year, with net profit attributable to shareholders of 246 million yuan versus a net loss of 30 million yuan in the first half of 2025.
Source:Aug 13, 2026, 00:04 UTC
The U.S. Food and Drug Administration completed several key steps in its review of Inovio Pharmaceuticals' biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis.
Source:Aug 12, 2026, 23:17 UTC
Inovio Pharmaceuticals, Inc. held its Q2 2026 earnings call on August 12, 2026.
Source:Jul 29, 2026, 20:01 UTC
INOVIO Pharmaceuticals announced a proposed public offering of shares of its common stock and accompanying warrants.
Source: